Trevena (NASDAQ:TRVN) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Trevena (NASDAQ:TRVN) in a report published on Wednesday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright decreased their price target on shares of Trevena from $9.00 to $5.00 and set a buy rating on the stock in a research note on Thursday, May 16th.

Trevena Trading Up 5.7 %

Shares of NASDAQ TRVN opened at $0.22 on Wednesday. The stock has a market cap of $4.03 million, a price-to-earnings ratio of -0.08 and a beta of 1.05. Trevena has a 52 week low of $0.19 and a 52 week high of $1.12. The company’s 50-day moving average price is $0.36 and its 200 day moving average price is $0.49.

Trevena (NASDAQ:TRVN) last issued its quarterly earnings data on Wednesday, May 15th. The biopharmaceutical company reported ($0.36) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.01. The business had revenue of $0.02 million during the quarter. As a group, research analysts expect that Trevena will post -1.29 earnings per share for the current year.

Institutional Trading of Trevena

An institutional investor recently bought a new position in Trevena stock. Armistice Capital LLC acquired a new position in Trevena, Inc. (NASDAQ:TRVN) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 797,714 shares of the biopharmaceutical company’s stock, valued at approximately $576,000. Armistice Capital LLC owned 4.61% of Trevena at the end of the most recent reporting period. 13.56% of the stock is currently owned by hedge funds and other institutional investors.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.